Skip to content

Text Size: AAA

Investors

Printer Friendly Version Print  |  E-mail this page Email  |  E-mail Alerts Alerts  |  RSS RSS  |  View contacts Contacts  |  Download Financial Tear Sheet Tear Sheet

Our Investor Relations Center is provided to give you convenient access to company information, including financial reports, press releases and corporate events. You can also sign up to be reminded via email of any upcoming company presentations, or to be notified of news releases and other announcements.

If you cannot find the information you're looking for on our website please let us know, and we will do our best to accommodate your request.
Featured Report
Download Documentation 2009 Annual Report
RECEIVE E-MAIL ALERTS
Alerts are e-mailed to you whenever certain new company information is posted to this site.
Sign-up Now!
Stock Quote
AMLN (Common)
ExchangeNASDAQ (US Dollar)
Price$21.44
Change (%) Stock is Up 0.50 (2.39%)
Volume1,113,074
Data as of 09/02/10 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore
DateTitle 
07/27/10Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010
SAN DIEGO, July 27, 2010 /PRNewswire via COMTEX/ --Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Wedbush Securities Life Sciences Best Ideas MAC: Management Access Conference in New York on Tuesday, August 3, 2010 at 10:35 a.m. ET / 7:35 a.m. PT. Alex Casdin, vice president, finance of Amylin Pharmaceuticals, will provide a corporate overview. The presentation will be webcast live through the "Investors" section of Amylin's corporate Web site at www.amylin.com, and ... 
Printer Friendly Version
07/21/10Amylin Pharmaceuticals Reports Second Quarter Financial Results
Year-to-Date Non-GAAP Operating Loss of $11.2 Million Improves by 74% Compared to 2009 Data Presented at ADA Further Demonstrated Safety and Efficacy Profiles of BYDUREON and BYETTA SAN DIEGO, July 21, 2010 /PRNewswire via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended June 30, 2010. The Company reported total revenue of $164.4 million for the quarter ended June 30, 2010, which includes net product sales of $162.5 million. Net l... 
Printer Friendly Version
07/14/10Amylin Pharmaceuticals to Webcast Second Quarter Results
SAN DIEGO, July 14, 2010 /PRNewswire via COMTEX/ --Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the second quarter of 2010 on Wednesday, July 21, 2010 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. On the same date post-market, Amylin will release financial results for the second quarter of 2010. The call will be webcast live through the "Investors" section of Amylin's... 
Printer Friendly Version
06/26/10Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010
Study Showed Improvements Compared to Lantus(R) ORLANDO, Fla., June 26, 2010 /PRNewswire via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a study comparing the effect of long-term treatment with either BYETTA(R) (exenatide) injection or Lantus(R) (insulin glargine) on overall beta-cell function. (Beta cells are cells in the pancreas that produce insulin.) Three years of BYETTA therapy improved indices of beta-cell fu... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.